CN111840564A - 一种二氧化锰基纳米药物载体及其制备方法和应用 - Google Patents
一种二氧化锰基纳米药物载体及其制备方法和应用 Download PDFInfo
- Publication number
- CN111840564A CN111840564A CN202010756035.3A CN202010756035A CN111840564A CN 111840564 A CN111840564 A CN 111840564A CN 202010756035 A CN202010756035 A CN 202010756035A CN 111840564 A CN111840564 A CN 111840564A
- Authority
- CN
- China
- Prior art keywords
- hsa
- solution
- mno
- hours
- deionized water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 title claims abstract description 138
- 239000003937 drug carrier Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 14
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 57
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 57
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 57
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 57
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 45
- 229930064664 L-arginine Natural products 0.000 claims abstract description 42
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 42
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 25
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 24
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 24
- 235000019152 folic acid Nutrition 0.000 claims abstract description 21
- 239000011724 folic acid Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 17
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 229960000304 folic acid Drugs 0.000 claims abstract description 14
- 230000008685 targeting Effects 0.000 claims abstract description 12
- 238000001179 sorption measurement Methods 0.000 claims abstract description 7
- 230000033558 biomineral tissue development Effects 0.000 claims abstract description 6
- 235000018102 proteins Nutrition 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 77
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 239000008367 deionised water Substances 0.000 claims description 42
- 229910021641 deionized water Inorganic materials 0.000 claims description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 33
- 238000004090 dissolution Methods 0.000 claims description 27
- 238000000502 dialysis Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 9
- 238000007710 freezing Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- 229940014144 folate Drugs 0.000 claims description 7
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 239000011565 manganese chloride Substances 0.000 claims description 4
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 229940099607 manganese chloride Drugs 0.000 claims description 3
- 235000002867 manganese chloride Nutrition 0.000 claims description 3
- 229910001437 manganese ion Inorganic materials 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 229940124280 l-arginine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 abstract description 20
- 238000002560 therapeutic procedure Methods 0.000 abstract description 15
- 235000003642 hunger Nutrition 0.000 abstract description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 8
- 230000037351 starvation Effects 0.000 abstract description 8
- 238000012377 drug delivery Methods 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229940043267 rhodamine b Drugs 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010756035.3A CN111840564B (zh) | 2020-07-31 | 2020-07-31 | 一种二氧化锰基纳米药物载体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010756035.3A CN111840564B (zh) | 2020-07-31 | 2020-07-31 | 一种二氧化锰基纳米药物载体及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111840564A true CN111840564A (zh) | 2020-10-30 |
CN111840564B CN111840564B (zh) | 2022-07-05 |
Family
ID=72945846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010756035.3A Active CN111840564B (zh) | 2020-07-31 | 2020-07-31 | 一种二氧化锰基纳米药物载体及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111840564B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112741930A (zh) * | 2020-12-22 | 2021-05-04 | 四川大学 | 一种酶改性的抗凝血瓣膜及其制备方法 |
CN113101370A (zh) * | 2021-04-08 | 2021-07-13 | 曲阜师范大学 | 一种二氧化锰靶向纳米药物载体及其制备方法、应用 |
CN113813402A (zh) * | 2021-09-30 | 2021-12-21 | 中国药科大学 | 一种具有饥饿联合气体疗法抗肿瘤功能的纳米凝胶的制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969765A (zh) * | 2018-06-27 | 2018-12-11 | 湖北大学 | 一种MnO2载体包覆药物前驱体5-ALA的制备方法 |
CN110743012A (zh) * | 2019-10-31 | 2020-02-04 | 新乡医学院 | 一种葡萄糖氧化酶修饰的介孔二氧化锰药物组合物的制备方法及应用 |
-
2020
- 2020-07-31 CN CN202010756035.3A patent/CN111840564B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969765A (zh) * | 2018-06-27 | 2018-12-11 | 湖北大学 | 一种MnO2载体包覆药物前驱体5-ALA的制备方法 |
CN110743012A (zh) * | 2019-10-31 | 2020-02-04 | 新乡医学院 | 一种葡萄糖氧化酶修饰的介孔二氧化锰药物组合物的制备方法及应用 |
Non-Patent Citations (3)
Title |
---|
DR. WENPEI FAN 等: "Glucose-Responsive Sequential Generation of Hydrogen Peroxide and Nitric Oxide for Synergistic Cancer Starving-Like/Gas Therapy", 《ANGEW CHEM INT ED ENGL》 * |
包忠妹 等: "叶酸修饰的白蛋白纳米粒的制备及理化性质的研究", 《广州化工》 * |
施德太等: "血清白蛋白:用于肿瘤精准诊疗的多元化载体", 《化学通报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112741930A (zh) * | 2020-12-22 | 2021-05-04 | 四川大学 | 一种酶改性的抗凝血瓣膜及其制备方法 |
WO2022135453A1 (zh) * | 2020-12-22 | 2022-06-30 | 吉林启明皓月生物科技有限公司 | 一种酶改性的抗凝血瓣膜及其制备方法 |
CN113101370A (zh) * | 2021-04-08 | 2021-07-13 | 曲阜师范大学 | 一种二氧化锰靶向纳米药物载体及其制备方法、应用 |
CN113813402A (zh) * | 2021-09-30 | 2021-12-21 | 中国药科大学 | 一种具有饥饿联合气体疗法抗肿瘤功能的纳米凝胶的制备方法和应用 |
CN113813402B (zh) * | 2021-09-30 | 2024-02-27 | 中国药科大学 | 一种具有饥饿联合气体疗法抗肿瘤功能的纳米凝胶的制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111840564B (zh) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111840564B (zh) | 一种二氧化锰基纳米药物载体及其制备方法和应用 | |
Zhang et al. | Erythrocyte membrane cloaked metal–organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy | |
Zhao et al. | Hyaluronic acid and carbon dots-gated hollow mesoporous silica for redox and enzyme-triggered targeted drug delivery and bioimaging | |
Shao et al. | Biomimetic nanoreactor for targeted cancer starvation therapy and cascade amplificated chemotherapy | |
Yao et al. | Dual-functional carbon dot-labeled heavy-chain ferritin for self-targeting bio-imaging and chemo-photodynamic therapy | |
CN110680926B (zh) | 一种纳米诊疗剂及其制备方法与应用 | |
CN112933251B (zh) | 四氧化三锰纳米颗粒制备方法及用途 | |
Wang et al. | Room-temperature preparation of coordination polymers for biomedicine | |
CN104667289B (zh) | 一种抗肿瘤药物载体及其使用方法 | |
Yu et al. | Self-preparation system using glucose oxidase-inspired nitroreductase amplification for cascade-responsive drug release and multidrug resistance reversion | |
KR20140048008A (ko) | 효소 반응성 그라핀 옥사이드/생체 고분자-광감각제 나노복합체 및 이를 포함하는 형광 영상 진단 또는 광역학/광열 치료용 조성물 | |
CN108310397B (zh) | 一种具有sers/荧光双模态靶向肿瘤细胞成像的诊疗试剂及其制备方法 | |
Liu et al. | Ag@ S-nitrosothiol core–shell nanoparticles for chemo and photothermal synergistic tumor targeted therapy | |
CN111939273A (zh) | 一种以铁蛋白为载体肿瘤纳米探针的制备方法 | |
CN112773899A (zh) | 一种基于生物金属有机骨架材料的药物递送载体及其制备方法和应用 | |
Qin et al. | Multi-responsive drug delivery nanoplatform for tumor-targeted synergistic photothermal/dynamic therapy and chemotherapy | |
Wang et al. | Trace-Water-Induced Competitive Coordination Synthesis and Functionalization of Porphyrinic Metal–Organic Framework Nanoparticles for Treatment of Hypoxic Tumors | |
CN108126199B (zh) | 一种可降解双响应智能高分子/硫化钼药物载体的制备方法 | |
Wang et al. | Recent advances in amino acid-metal coordinated nanomaterials for biomedical applications | |
CN100461310C (zh) | 双功能磁流体及其制备方法 | |
Ozsoy et al. | Activities of gallic acid and Fe doped, and glucose oxidase or gold modified ZIF-8 based drug delivery systems in triple negative breast cancer | |
CN110917349B (zh) | 一种碗状isp复合功能性纳米粒子及其制备方法和应用 | |
CN114939165B (zh) | 可逆转多药耐药性的双金属纳米粒及其制备方法和应用 | |
Liao et al. | Multifunctional nanogel based on carboxymethyl cellulose interfering with cellular redox homeostasis enhances phycocyanobilin photodynamic therapy | |
Chen et al. | Nanodrugs mediate TAMs-related arginine metabolism interference to boost photodynamic immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Gong Peiwei Inventor after: Liu Zhe Inventor after: Peng Jingyi Inventor after: Liu Mingyue Inventor after: Huang Yan Inventor after: Li Hui Inventor after: Zhai Mingzhu Inventor before: Gong Peiwei Inventor before: Peng Jingyi Inventor before: Liu Zhe Inventor before: Liu Mingyue Inventor before: Huang Yan Inventor before: Li Hui Inventor before: Zhai Mingzhu |
|
GR01 | Patent grant | ||
GR01 | Patent grant |